Gapping down
In reaction to earnings/guidance:
- PBA -2.1%, .
M&A news:
- AZN -5.5% (Alexion Pharma to be acquired by AstraZeneca (AZN) for $175 per share)
Other news:
- ARPO -42.2% (Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial)
- SPCE -14.2% (announces an update following its recent test flight on December 12, 2020; rocket motor did not fire due to the ignition sequence not completing)
- GMDA -13.8% (conducted a Type B Meeting for omidubicel with the FDA; Feedback supports proceeding to BLA Submission for omidubicel with additional manufacturing requirements)
- NIO -5.3% (prices offering of 68,000,000 ADSs at a price of $39.00 per ADS)
- SALT -4.6% (files for $500 mln mixed securities shelf offering; also files for 3,107,751 share common stock offering by selling shareholders)
- VXX -3.3% (trading lower with strength in Futures)
- ZNGA -3.1% (private offering of $750 million of convertible senior notes)
- MIRM -2.5% (commences public offering to issue and sell $75.0 mln of shares of its common stock) CMT -2.3% (files for $50 mln mixed securities shelf offering)
- NLTX -1.9% (files for $400 mln mixed securities shelf offering)
- TTGT -1.9% (announced that it proposes to offer $175 mln aggregate principal amount of convertible senior notes due 2025)
- TGTX -1% (commences underwritten public offering of $200 mln of common stock)
- NVS -0.9% (provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19)
Analyst comments:
- ABNB -3% (downgraded to Underperform rom Buy at Gordon Haskett)
- MIK -1.3% (downgraded to Neutral from Overweight at JP Morgan)
- DIS -0.8% (downgraded to Market Perform from Outperform at BMO Capital Markets)